Ethylketazocine

From WikiMD's WELLNESSPEDIA

Ethylketazocine is a synthetic compound of the benzomorphan class of opioids. It was developed in the 1960s as a potential analgesic medication but was never marketed. Ethylketazocine has been used in scientific research, particularly in studies involving the opioid receptor system.

Chemistry[edit]

Ethylketazocine is a member of the benzomorphan class of opioids, which also includes drugs such as pentazocine and phenazocine. It is a synthetic compound, meaning it is not derived from natural sources such as the opium poppy. The chemical structure of ethylketazocine includes a benzene ring fused to a morphinan skeleton, hence the name "benzomorphan."

Pharmacology[edit]

Ethylketazocine acts as an agonist at the kappa opioid receptor (KOR), one of the three main types of opioid receptors in the body. It has also been found to have some activity at the mu opioid receptor (MOR) and the delta opioid receptor (DOR), although its effects at these receptors are less well understood.

Research[edit]

Although ethylketazocine was never marketed as a medication, it has been used in scientific research. Studies have used ethylketazocine to investigate the function of the KOR, as well as the effects of KOR agonists on pain and other physiological processes. Some research has suggested that ethylketazocine and other KOR agonists may have potential as treatments for conditions such as depression and anxiety, although more research is needed in this area.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.